Table 3 Association of immunoregulatory SNPs and risk of developing acute myeloid leukaemia.

From: Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium

Gene name

dbSNP rs#

Gene symbol_SNP

Risk allele

Discovery Population (n = 2027)

338 AML cases and 1689 healthy controls

PCorr

Replication Population (n = 2104)

316 AML cases and 1788 healthy controls

Overall Population (n = 4131)

654 AML cases and 3477 healthy controls

PCorr

OR (95% CI)a

P

OR (95% CI)a

P

OR (95% CI)a

P

IL4

rs2243248

IL4_-1098

G

4.33 (1.37–13.7)b

0.012

0.864

1.75 (0.31–9.67)b

0.52

3.09 (1.26–7.58)b

0.014

1.000

IL4

rs2243268

IL4_IVS2-1443

C

1.31 (1.01–1.69)

0.042

1.000

0.87 (0.66–1.15)

0.32

1.09 (0.90–1.31)

0.39

1.000

IL8

rs4073

IL8_-251

A

0.81 (0.67–0.97)

0.020

1.000

0.96 (0.76–1.20)

0.70

0.89 (0.78–1.01)

0.072

1.000

IL8

rs2227307

IL8_ IVS1 + 230 (+396)

G

0.70 (0.53–0.92)c

0.012

0.864

0.74 (0.56–0.99)c

0.040

0.72 (0.59–0.87)c

0.0010

0.072

IL8RB

rs1126580

CXCR2_Ex3-1010

A

0.82 (0.68–1.00)

0.044

1.000

1.05 (0.87–1.27)

0.61

0.95 (0.83–1.09)

0.49

1.000

IL12A

rs568408

IL12A_Ex7 + 277

A

2.48 (1.00–6.15)b

0.050

1.000

1.07 (0.35–3.32)b

0.90

1.66 (0.84–3.27)b

0.14

1.000

IL12B

rs3212227

IL12B_Ex8 + 159 (+1188)

C

0.99 (0.79–1.25)

0.96

1.000

     

IL13

rs1800925

IL13_-1069

T

1.01 (0.80–1.28)

0.93

1.000

     

IL13

rs20541

IL13_Ex4 + 98

T

1.98 (1.08–3.65)b

0.028

1.000

1.75 (0.90–3.39)b

0.10

1.89 (1.21–2.94)b

0.0048

0.346

IL13

rs1295686

IL13_IVS3-24

A

2.16 (1.19–3.93)b

0.012

0.864

2.24 (1.27–3.93)b

0.0051

2.18 (1.45–3.26)b

0.0002

0.0144

IFNG

rs2069705

INFG_-1615

C

1.10 (0.90–1.35)

0.34

1.000

     

IFNG

rs1861494

INFG_IVS3 + 284 (+2109)

C

1.19 (0.96–1.47)

0.12

1.000

     

IFNGR2

rs1059293

INFGR2_Ex7-128

T

1.51 (1.11–2.05)c

0.0074

0.533

0.90 (0.67–1.21)c

0.48

1.16 (0.94–1.43)c

0.16

1.000

IFNGR2

rs9808753

INFGR2_Ex2-16

G

1.05 (0.79–1.41)

0.73

1.000

     

CCR5

rs1799987

CCR5_IVS1 + 246

G

0.82 (0.67–0.99)

0.043

1.000

0.98 (0.81–1.19)

0.85

0.90 (0.79–1.03)

0.13

1.000

CCR5

rs2734648

CCR5_IVS1 + 151

T

0.75 (0.61–0.92)

0.0044

0.317

1.12 (0.93–1.36)

0.24

0.93 (0.81–1.06)

0.27

1.000

MIF

rs755622

MIF_-173

G

0.88 (0.67–1.14)

0.32

1.000

     

VEGFA

rs699947

VEGFA_-2578

A

1.05 (0.87–1.27)

0.58

1.000

     

VEGFA

rs25648

VEGFA_-7

T

0.42 (0.29–0.62)c

0.00002

0.0014

0.79 (0.58–1.06)c

0.12

0.60 (0.47–0.75)c

0.000012

0.00086

VEGFA

rs3024994

VEGFA_IVS2 + 1378

T

0.87 (0.59–1.29)

0.49

1.000

     

VEGFA

rs3025035

VEGFA_IVS7-919

T

1.08 (0.79–1.48)

0.62

1.000

     

VEGFA

rs2146323

VEGFA_6112

A

1.01 (0.82–1.23)

0.95

1.000

     

VEGFA

rs3024997

VEGFA_IVS-99

A

1.01 (0.83–1.24)

0.91

1.000

     

VEGFA

rs3025030

VEGFA_IVS7 + 763

C

0.95 (0.72–1.26)

0.72

1.000

     

VEGFA

rs998584

VEGFA_5530

T

1.40 (1.03–1.89)b

0.034

1.000

1.08 (0.80–1.47)b

0.61

1.24 (1.00–1.54)b

0.048

1.000

VEGFA

rs6899540

VEGFA_5958bp 3’of STP

C

1.01 (0.77–1.32)

0.93

1.000

     

VEGFA

rs6900017

VEGFA_6119bp 3’of STP

T

0.94 (0.68–1.30)

0.72

1.000

     
  1. Association estimates were adjusted for sex and country of origin. P < 0.05 in bold. Corrected P-value was calculated by multiplying the unadjusted P-value by the number of tests performed (n = 72, 24 SNPs by 3 inheritance models tested).
  2. SNP single nucleotide polymorphisms, OR odds ratio, CI confidence interval.
  3. aEstimates were calculated according to an additive model of inheritance.
  4. bEstimates were calculated according to a recessive model of inheritance.
  5. cEstimates were calculated according to a dominant model of inheritance.
Back to article page